Intelligence · Clinical pipeline
Neurology & CNS R&D Pipeline
Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.
Quick answer
Neurology & CNS: NovaPharmaNews indexes 675 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.
Top sponsors
- HOFFMANN-LA ROCHE 37 programs
- Teva Pharma 37 programs
- Takeda 32 programs
- BRIGHT MINDS BIOSCIENCES 30 programs
- United Therapeutics Europe 26 programs
- Chinese Academy of 24 programs
- Anaxis Pharma 21 programs
- Novartis India 21 programs
- Jazz Pharmaceuticals Ireland 20 programs
- NEUROCRINE BIOSCIENCES 18 programs
- SUPERNUS PHARMACEUTICALS 18 programs
- Acadia Pharmaceuticals 16 programs
Pipeline programs
-
0.2 mg/kg ketamine
United Therapeutics Europe Ltd
Depression
1 trial -
105MS306
Biogen
Relapsing Remitting Multiple Sclerosis (RRMS)
1 trial -
116130
Disc Medicine
Parkinson's disease
1 trial -
11C-SB207145, 11C-DASB
The George Institute
Parkinson's disease, Prodromal phase of Parkinson's disease
1 trial -
1346-0014
Boehringer Ingelheim
Schizophrenia
1 trial -
160701
Takeda
Alzheimer´s Disease
1 trial -
161003
Takeda
Alzheimer´s Disease
1 trial -
161202
Takeda
Alzheimer´s Disease
1 trial -
18F-AV-1451
The George Institute
Maladie d' Alzheimer, Alzheimer's pathology
1 trial -
18F-DPA-714
Pari Pharma GmbH
Multiple sclerosis
1 trial -
2.16/VI/22
Cardiol Therapeutics
Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.
1 trial -
20-AVP-786-306
Otsuka Beijing Research Institute
Agitation in Patients With Dementia of the Alzheimer's Type
1 trial -
20190531
Amgen
Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).
1 trial -
20230309
Amgen
Relapsing-remitting Multiple Sclerosis
1 trial -
40 mg/day vormatrogine for 12 weeks
Chongqing Precision Biotech Co., Ltd
Focal Epilepsy
1 trial -
42-1703
Aquestive Therapeutics
Epilepsy
1 trial -
AB20009
AB Science
Multiple Sclerosis
1 trial -
ACP-204
Acadia Pharmaceuticals B.V.
Alzheimer's Disease Psychosis
2 trials -
ACP-204-008
Lacuna Pharma Pty Ltd
Alzheimer's Disease Psychosis
1 trial -
ALKS 9072
Alkermes Pharma Ireland
Schizophrenia
1 trial -
ALKS 9072, Low Dose
Alkermes Pharma Ireland
Schizophrenia
1 trial -
APHP200056
Pari Pharma GmbH
Remyelination in Multiple Sclerosis
1 trial -
APHP230836
Pari Pharma GmbH
Patients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in nature, occurs within a 72 hour window, and consists of a decrease in hearing of ≥30 decibels affecting at least 3 consecutive frequencies: 1. A history of an idiopathic and unilateral sudden decrease in hearing > 72 hours and <15 days. 2. A unilateral sensorineural hearing loss demonstrable on a pure‐tone audiogram at the time of entry into the trial. 3. No other neurological signs except the eight cranial nerve defect; no other types of hearing loss as conductive forms of hearing impairment. 4. No history of fluctuating sensorineural hearing loss or otologic disease.
1 trial -
AVP-786 matching placebo, AVP-786
Otsuka Beijing Research Institute
Agitation in Patients With Dementia of the Alzheimer's Type
1 trial -
AXS-05
Axsome Therapeutics
Agitation in Patients With Dementia of the Alzheimer's Type
3 trials -
AXS-05
Axsome Therapeutics
Depression
1 trial -
AXS-05 (dextromethorphan-bupropion)
Axsome Therapeutics
Agitation in Patients With Dementia of the Alzheimer's Type
2 trials -
Amlodipine
United Therapeutics Europe Ltd
Depression
1 trial -
Apitox - pure honeybee toxin
Apimeds Pharmaceuticals US
Multiple Sclerosis
1 trial -
Aripiprazole IM Depot
Otsuka Beijing Research Institute
Schizophrenia
1 trial -
Armodafinil
Teva Pharma GmbH
Depression
4 trials -
Asenapine Sublingual Tablets 10 mg
Amneal Pharma Europe Ltd
Schizophrenia
1 trial -
Azeliragon
vTv Therapeutics
Alzheimer's Disease
1 trial -
Azeliragon 5mg
vTv Therapeutics
Alzheimer's Disease
1 trial -
Azetukalner
Xenon Pharmaceuticals
Bipolar Depression
1 trial -
BG00012
Biogen
Relapsing-Remitting Multiple Sclerosis
1 trial -
BHV7000-303
Biohaven Bioscience Ireland Limited
Refractory Focal Onset Epilepsy
1 trial -
BHV7000-304
Biohaven Bioscience Ireland Limited
Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures
1 trial -
BHV8000-301
Biohaven Bioscience Ireland Limited
Early Parkinson’s Disease
1 trial -
BIIB019 (Daclizumab)
Biogen
Relapsing-Remitting Multiple Sclerosis
1 trial -
BIIB122
Denali Therapeutics
Parkinson Disease
2 trials -
BN42082
Hoffmann-La Roche
Relapsing Multiple Sclerosis (MS)
1 trial -
BN42083
Hoffmann-La Roche
Primary Progressive Multiple Sclerosis (PPMS)
1 trial -
BN42358
Hoffmann-La Roche
Early Parkinson's disease
1 trial -
Bifeprunox
H. Lundbeck A/S
Schizophrenia
1 trial -
Brexanolone
SUPERNUS PHARMACEUTICALS, INC.
Post Partum Depression
1 trial -
Brilaroxazine
REVIVA PHARMACEUTICALS HOLDINGS, INC.
Schizophrenia
1 trial -
Brivaracetam
UCB Pharma
Epilepsy
1 trial
Frequently asked questions
How many neurology & cns pipeline programs are tracked?
675 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.